Syndax Pharmaceuticals, Inc. (SNDX) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Previous Close | 19 |
| Open | 19.21 |
| Day High | 19.59 |
| Day Low | 18.94 |
| 52-Week High | 25.59 |
| 52-Week Low | 8.59 |
| Volume | 1.78M |
| Average Volume | 1.72M |
| Market Cap | 1.71B |
| PE | -6.92 |
| EPS | -2.79 |
| Moving Average 50 Days | 20.46 |
| Moving Average 200 Days | 19.5 |
| Change | 0.32 |
Syndax to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call and Webcast on February 26, 2026
GlobeNewswire Inc.
Feb 19, 2026 12:00 PM GMT
NEW YORK, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will report its fourth quarter and full year 2025 financi
Syndax Announces Participation at the 2026 Guggenheim Emerging Outlook: Biotech Summit
GlobeNewswire Inc.
Feb 05, 2026 12:00 PM GMT
NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, will participat
Syndax Reports Preliminary 2025 Financial Highlights and Provides Business Updates at the 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 12, 2026 12:00 PM GMT
– Approximately $44 million and $125 million in preliminary (unaudited) Revuforj® (revumenib) 4Q25 and full year 2025 net revenue, respectively – – Continued acceleration in demand following approval in R/R NPM1m AML, with an approximate 38% increa